Browse News
Filter News
Found 723,086 articles
-
The approval marks the first for EoE, a chronic, progressive type 2 inflammatory disease that damages the eosinophilic esophagitis and prevents it from working properly.
-
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
-
The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
-
Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year.
-
A study conducted by Athersys' partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.
-
Rice University researchers used the foundation of CRISPR/Cas9 technology and developed “drive-and-process” arrays, or DAP for short.
-
Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.
-
According to researchers at the Universite Sorbonne Paris Nord, Universite Paris-Saclay, ants can be trained to sniff out the specific odors associated with certain cancers.
-
The Zymeworks Board of Directors has rejected an acquisition proposal from activist investor All Blue Falcons FZE, calling the attempt “opportunistic.”
-
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Pancreatic transplants are difficult to pull off for Type 1 diabetes, but new technology may make it possible, and infusions of spinal fluid from young mice to older ones reportedly reverses memory loss.
-
BioSpace spoke with four veterans in the field about the less obvious reasons why companies with good science may still fail.
-
AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease
5/20/2022
AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).
-
FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder
5/20/2022
Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds).
-
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
5/20/2022
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
-
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
5/20/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
-
Novel Immunotherapy Developed by City of Hope Could Provide New Treatment Model for SARS-CoV-2 Patients
5/20/2022
City of Hope researchers have engineered an immunotherapy using natural killer cells with a specific molecule that can target the SARS-CoV-2 virus’ spike protein, providing a novel therapeutic pathway for the treatment of COVID-19 and other infections that include the spike protein, according to a study published in Nature Communications.